The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
Open accessAbstract
// Corinna Eichelser 1, * , Isabel Stückrath 1, * , Volkmar Müller 2 , Karin Milde-Langosch 2 , Harriet Wikman 1 , Klaus Pantel 1 , Heidi Schwarzenbach 1 1 Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany 2 Clinic of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany * These authors contributed equally to this work Correspondence to: Heidi Schwarzenbach, e-mail: hschwarz@uke.uni-hamburg.de Keywords: cell-free miRs, exosomal miRs, estrogen receptor, luminal breast cancer Received: June 27, 2014 Accepted: August 28, 2014 Published: October 07, 2014 ABSTRACT In this study, we compared the blood serum levels of circulating cell-free and exosomal microRNAs, and their involvement in the molecular subtypes of breast cancer patients. Our analyses on cell-free miR-101, miR-372 and miR-373 were performed in preoperative blood serum of 168 patients with invasive breast cancer, 19 patients with benign breast diseases and 28 healthy women. MicroRNAs were additionally quantified in exosomes of 50 cancer patients and 12 healthy women from the same cohort. Relative concentrations were measured by quantitative TaqMan MicroRNA assays and correlated to clinicopathological risk factors. The concentrations of cell-free miR-101 (p=0.013) and miR-373 (p=0.024) were significantly different between patients with breast cancer and benign tumors. A prevalence of miR-101, miR-372 and miR-373 were found in exosomes. The levels of circulating exosomal (but not cell-free) miR-373 were higher in triple negative than luminal carcinomas (p=0.027). Also, estrogen-negative (p=0.021) and progesterone-negative (p=0.01) tumors displayed higher concentrations of exosomal miR-373 than patients with hormone-receptor positive tumors. Overexpression of miR-373 by transfection of MCF-7 cells showed downregulated protein expression of the estrogen receptor, and inhibition of apoptosis induced by camptothecin. Our data indicate that serum levels of exosomal miR-373 are linked to triple negative and more aggressive breast carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Self-citationThe microRNA.org resource: targets and expression
Betel, D., Wilson, M., Gabow, A., Marks, D. S., & Sander, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm995 · Cited by 2,503
Remmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
(2005) · doi:10.1093/nar/gki200 · Cited by 1,208
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
Kosaka, N., Iguchi, H., & Ochiya, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01650.x · Cited by 1,147
Exosomes: proteomic insights and diagnostic potential
Simpson, R. J., Lim, J. W., Moritz, R. L., & Mathivanan, S. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.17 · Cited by 1,108
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D. A., Li, A., Huang, G., Klein-Szanto, A. J., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1681 · Cited by 975
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S.-F., Dunning, M. J., Barbosa-Morais, N. L., Teschendorff, A. E., Green, A. R., Ellis, I. O., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-10-r214 · Cited by 948
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., & Leal, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293659 · Cited by 887
Yang, M., Chen, J., Su, F., Yu, B., Su, F., Lin, L., Liu, Y., Huang, J.-D., & Song, E. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-117 · Cited by 693
DIANA-microT web server: elucidating microRNA functions through target prediction
Maragkakis, M., Reczko, M., Simossis, V. A., Alexiou, P., Papadopoulos, G. L., Dalamagas, T., Giannopoulos, G., Goumas, G., Koukis, E., Kourtis, K., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp292 · Cited by 562
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Cortez, M. A., & Calin, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932889 · Cited by 436
Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage
Rupp, A.-K., Rupp, C., Keller, S., Brase, J. C., Ehehalt, R., Fogel, M., Moldenhauer, G., Marmé, F., Sültmann, H., & Altevogt, P. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.035 · Cited by 301
Leivonen, S.-K., Mäkelä, R., Östling, P., Kohonen, P., Haapa-Paananen, S., Kleivi, K., Enerly, E., Aakula, A., Hellström, K., Sahlberg, N., et al. (2009) · Oncogene · doi:10.1038/onc.2009.241 · Cited by 243
Smits, M., Nilsson, J., Mir, S. E., van der Stoop, P. M., Hulleman, E., Niers, J. M., de Witt Hamer, P. C., Marquez, V. E., Cloos, J., Krichevsky, A. M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.205 · Cited by 236
Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls
Hu, Z., Dong, J., Wang, L.-E., Ma, H., Liu, J., Zhao, Y., Tang, J., Chen, X., Dai, J., Wei, Q., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs030 · Cited by 215
Hiroki, E., Akahira, J., Suzuki, F., Nagase, S., Ito, K., Suzuki, T., Sasano, H., & Yaegashi, N. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01385.x · Cited by 214
Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.205161 · Cited by 195
Self-citationvan Schooneveld, E., Wouters, M. C., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2012) · Breast Cancer Research · doi:10.1186/bcr3127 · Cited by 191
Chen, W., Cai, F., Zhang, B., Barekati, Z., & Zhong, X. Y. (2013) · Tumor Biology · doi:10.1007/s13277-012-0570-5 · Cited by 177
Lee, K.-H., Goan, Y.-G., Hsiao, M., Lee, C.-H., Jian, S.-H., Lin, J.-T., Chen, Y.-L., & Lu, P.-J. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.06.001 · Cited by 175
Zhang, J.-G., Guo, J.-F., Liu, D.-L., Liu, Q., & Wang, J.-J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318208eb35 · Cited by 173
MicroRNAs as Novel Biomarkers for Breast Cancer
Heneghan, H., Miller, N., Lowery, A., Sweeney, K. J., & Kerin, M. J. (2009) · Journal of Oncology · doi:10.1155/2010/950201 · Cited by 153
Zhou, A.-D., Diao, L.-T., Xu, H. M., Xiao, Z.-D., Li, J.-H., Zhou, H., & Qu, L.-H. (2011) · Oncogene · doi:10.1038/onc.2011.461 · Cited by 140
MicroRNA-101-mediated Akt activation and estrogen-independent growth
Sachdeva, M., Wu, H., Ru, P., Hwang, L., Trieu, V. N., & Mo, Y.-Y. (2010) · Oncogene · doi:10.1038/onc.2010.463 · Cited by 123
The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma
Patterson, E., Webb, R., Weisbrod, A. B., Bian, B., He, M., Zhang, L., Holloway, A. K., Krishna, R., Nilubol, N., Pacák, K., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0308 · Cited by 73
MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1
Wang, R., Wang, H., Hao, C. J., Cui, Y., Han, X., Hu, Y., Li, F.-F., Xia, H.-F., & Ma, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046173 · Cited by 71
Invasive Breast Cancer: Recognition of Molecular Subtypes
Strehl, J. D., Wachter, D. L., Fasching, P. A., Beckmann, M. W., & Hartmann, A. (2011) · Breast Care · doi:10.1159/000331339 · Cited by 59
Semaan, A. Y., Qazi, A. M., Seward, S. M., Chamala, S., Bryant, C. S., Kumar, S., Morris, R. T., Steffes, C. P., Bouwman, D. L., Munkarah, A. R., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0547-x · Cited by 59
Cited by
Effect of exosomal miRNA on cancer biology and clinical applications
Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800
Exosomes in cancer: small particle, big player
Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0181-x · Cited by 780
Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage
Wang, H., Peng, R., Wang, J., Qin, Z., & Xue, L. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0492-1 · Cited by 527
Exosomes: From Garbage Bins to Promising Therapeutic Targets
H. Rashed, M., Bayraktar, E., K. Helal, G., Abd-Ellah, M., Amero, P., Chavez-Reyes, A., & Rodriguez-Aguayo, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030538 · Cited by 525
Exosomes in Cancer Diagnostics
Soung, Y., Ford, S., Zhang, V., & Chung, J. (2017) · Cancers · doi:10.3390/cancers9010008 · Cited by 368
Metadata
- Authors
- Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K., & Schwarzenbach, H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-10-11
- Volume
- 5
- Issue
- 20
- Pages
- 9650-9663
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1528198209
- Cited by
- 376
- References
- 36
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.